Fig 1: Suppression of DRP1 reverses the pro-tumorigenic effects of FGF21 on proliferation and metabolism in LUSC.A CCK-8 assay showing the viability of DRP1-silenced H1703 and H520 cells with or without FGF21 treatment. B Colony formation capacity and viability of DRP1-silenced H1703 and H520 cells with or without FGF21 treatment. C, D Intracellular ATP levels and lactate production in DRP1-silenced cells treated with rhFGF21 (200 ng/ml, 24 h). E Immunofluorescence staining of mitochondria (Mito-Tracker Red) and nuclei (Hoechst33342) in H1703 and H520 cells treated with rhFGF21 (200 ng/ml, 12 h) after DRP1 siRNA transfection; scale bars, 10 μm. The individual mitochondria, network and footprints per cell were quantified. F MMP was assessed by JC-1 staining in DRP1-silenced H1703 and H520 cells treated with rhFGF21; scale bars, 200 μm. G, H Metabolic flux rescue. G The OCR and H ECAR profiles of DRP1-silenced LUSC cells treated with or without FGF21 were analyzed using the Seahorse XF platform. The data are shown as the means ± SEMs or SDs; *p < 0.05, **p < 0.01, ***p < 0.01, ****p < 0.01.
Fig 2: In vitro FGF21 promotes malignant phenotypes of LUSC cells.A Schematic workflow of the experimental design. B Dose- and time-dependent effects of FGF21 (25–200 ng/mL) on the viability of H1703 and H520 cells at 24 h, 48 h, and 72 h. C Colony formation capacity of cells treated with FGF21 and/or AZD4547. D Tumor sphere formation in serum-free medium supplemented with/without FGF21; scale bars, 200 μm. E Wound healing assay showing the lateral migration rates; scale bars, 50 μm. F Transwell invasion assay demonstrating the vertical migration rates; scale bars, 100 μm. The data are presented as the means ± SEMs (n = 3). *p < 0.05, **p < 0.01, ***p < 0.01, ****p < 0.0001.
Fig 3: FGF21 promotes mitochondrial fission and metabolic reprogramming in LUSC cells.A Live-cell imaging of mitochondria using Mito Tracker Red in H1703 and H520 cells after 12 h of treatment with rhFGF21 (200 ng/ml); scale bars, 10 μm. B Total ATP levels in LUSC cells treated with or without rhFGF21 were measured via a luminescence assay. C Quantitative analysis of lactate levels in conditioned media from LUSC cells treated with rhFGF21. D TOM-20-mediated mitochondrial morphology analysis. The number of individual mitochondria, network and footprints per cell were quantified, n = 6, scale bars, 10 μm. E The MMP was quantified by JC-1 staining (monomers: green; aggregates: red) in H1703 and H520 cells pretreated with rhFGF21 using confocal microscopy; scale bar, 200 μm. F, G Metabolic flux profiling. The OCR and ECAR were assessed using a Seahorse XF analyzer. Sequential additions: Oligo (1 μM), FCCP (0.5 μM), and Rot/AA (rotenone/antimycin) (0.5 μM each) for OCR; Glc (glucose) (10 mM), Oligo (oligomycin) (1 μM), and 2-DG (100 mM) for ECAR. The data are shown as the means ± SEMs or SDs; *p < 0.05, **p < 0.01, ***p < 0.01.
Supplier Page from MedChemExpress for FGF-21 Protein, Human